Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need
The Multi-Functional Cell Therapies Summit united global leaders to discuss strategies to weaponize cell therapies with antigenic, engineered, and combination approaches to create sophisticated multi-functional systems to treat solid tumors. We explored:
- Understanding and overcoming the immunosuppressive nature of the TME to inform future drug development
- Exploiting multiple functions through innovative engineering and novel targeting approaches to produce “smarter” cell therapies with high efficacy and safety profiles
- Synergizing analytical strategy with efficient and standardized manufacturing to overcome regulatory barriers preventing approval
Industry-Leading Speakers Included
Who Attended in 2022?
We brought together leading drug developers and innovators to tackle unique cell therapy development challenges creating obstacles for effective treatments for solid tumor patients.
Hear What Our Attendees Have to Say...
"I'm looking forward to speaking at the Multi-Functional Cell Therapies Summit and hearing about the exciting work of other leading investigators in this rapidly-developing approach to disease management."
Lawrence Lamb, CSO & EVP, In8bio
"Multi-Functional Cell Therapies are a key step for the industry to overcome challenges in solid tumors. This summit is an important gathering of the minds to advance the next generation of life-saving therapies"
Francesco Marincola, CSO, Refuge Biotech
“A truly professional forum to network and gain valuable insights into new trends in CAR-TCR development.”
Cheng Liu, CEO, Eureka Inc.
"Gain great insights into new trends and mix with the avant-garde in cell immunotherapy development"
Sicco Popma, CEO, IO Bio Science
"An outstanding forum to gain valuable insights into new trends in cell therapy development"
Hanspeter Gerber, CSO, 3T Biosciences
“A truly outstanding summit that provides a unique opportunity for cross-functional information and experience sharing, thereby showing the way forward in CAR-TCR development”
Peggy Sotiropoulou, Head of R&D, Celyad Oncology